Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (European commission: Executive Agency for Small and Medium-sized Enterprises – EASME).

2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission


2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission


2015 17th i-Lab “Créadev” BPI France


2013 15th “émergence” OSEO/BPI


2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.

Contact Info

Parc scientifique Biocitech
102 Avenue Gaston Roussel
Batiment Pasteur Secteur 2169
93230 Romainville - France

56 Boulevard de la Mission Marchand - 92400 Courbevoie France

Phone: +33 1 43 34 89 90

Mobile: +33 6 60 90 41 24

14 05, 2019

2019 – Milan, Italy – “Outsourcing in Clinical Trials Europe”

May 14th, 2019|0 Comments


Regulaxis’ President and CEO Claude Carelli and the CSO Christelle Vêtu participated to the OCT conference in Europe, in Milan, Italy, on May 14-15.

Follow us to

2 05, 2019

2019 – Toronto, Canada – OARSI World Congress

May 2nd, 2019|0 Comments

REGULAXIS is at the 2019 OARSI conference in Toronto from 2nd-5th of May !

OARSI World Congress on Osteoarthritis: Doctor Christelle Vêtu, CSO and Strategic Business Advisor will present the latest results during the poster session : “Chimeric Peptide combining both Growth Hormone and Somatostatin Sequences (REG-O3) improves function and prevents cartilage degradation in rat […]

26 04, 2018

2018 – Liverpool – OARSI World Congress on Osteoarthritis

April 26th, 2018|0 Comments

REGULAXIS, a leader in peptide research and development, will presents its most recent preclinical data of REG-O3, an innovative chimeric peptide for the treatment of osteoarthritis of knee at the 2018 Osteoarthritis Research Society International World Congress (OARSI), to be held April 26-29, 2018 in Liverpool, UK.

9 04, 2018

2018 – Macau, China – 14th World Congress of ICRS

April 9th, 2018|0 Comments

Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.
“REG-O3, new chimeric peptides regulating IGF-1 pathway: significant therapeutic effect on ACLT rabbit model of osteoarthritis”
Raffaello PAOLINI, Rodrick MONTJEAN and Christelle VETU